Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Homozygous familial hypercholesterolemia (HoFH) in Canada.

Atherosclerosis·2026
Same author

Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype.

Atherosclerosis·2026
Same author

Aortic Stenosis in Homozygous Familial Hypercholesterolemia: The Canadian HoFH Registry.

JACC. Advances·2026
Same author

Spectrum of DNA Variants in Southwestern Ontario Patients with Familial Hypercholesterolemia.

CJC open·2026
Same author

Imputation of untreated LDL-C in treated subjects with homozygous familial hypercholesterolaemia: An international collaboration.

Atherosclerosis·2025
Same author

Comparison of Patients With Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia Syndrome.

The Journal of clinical endocrinology and metabolism·2024

Related Experiment Video

Updated: Jul 4, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Polygenic determinants of severe hypertriglyceridemia.

Jian Wang1, Matthew R Ban, Guang Yong Zou

  • 1Vascular Biology Research Group 2 Clinical Trials Group, Robarts Research Institute and Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.

Human Molecular Genetics
|July 4, 2008
PubMed
Summary

Common genetic variants linked to mild triglyceride changes also contribute to severe hypertriglyceridemia. These findings support a complex genetic model for triglyceride levels.

Related Experiment Videos

Last Updated: Jul 4, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Cardiovascular Disease Risk

Background:

  • Genome-wide association studies (GWAS) have identified genetic factors influencing plasma triglyceride (TG) levels.
  • Severe hypertriglyceridemia (HTG) is a complex quantitative trait with a significant genetic component.
  • Understanding the genetic underpinnings of HTG is crucial for risk stratification and management.

Purpose of the Study:

  • To investigate whether common genetic variants associated with mild TG variations in GWAS are also associated with severe HTG.
  • To examine the contribution of specific common single nucleotide polymorphisms (SNPs) to the risk of severe hypertriglyceridemia.
  • To explore the genetic architecture of extreme triglyceride levels.

Main Methods:

  • Genotyping of 132 European ancestry patients with severe HTG and 351 normolipidemic controls.
  • Analysis of common variants in genes including GALNT2, TBL2/MLXIPL, TRIB1, ANGPTL3, GCKR, APOA5, APOE, and LPL.
  • Univariate and multivariate regression analyses to assess the association of genotypes with severe HTG, adjusting for diabetes and obesity.

Main Results:

  • Several genotypes, including those in APOA5, APOE, GCKR, TRIB1, and TBL2/MLXIPL, were significantly associated with severe HTG.
  • These associations remained significant regardless of diabetes or obesity status.
  • These common variants explained approximately one-quarter of the variation in disease status.

Conclusions:

  • Common SNPs identified in GWAS for mild TG variation are also associated with severe HTG.
  • These findings support a model where common alleles with small effects contribute to extreme quantitative traits.
  • The genetic basis of severe HTG involves the cumulative effects of multiple common variants.